- Home
- WSC vs NUVL Comparison
WSC vs NUVL Comparison
Compare WSC & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSC
- NUVL
- Stock Information
- Founded
- WSC 1944
- NUVL 2017
- Country
- WSC United States
- NUVL United States
- Employees
- WSC N/A
- NUVL N/A
- Industry
- WSC Misc Corporate Leasing Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- WSC Industrials
- NUVL Health Care
- Exchange
- WSC Nasdaq
- NUVL Nasdaq
- Market Cap
- WSC 5.3B
- NUVL 5.8B
- IPO Year
- WSC N/A
- NUVL 2021
- Fundamental
- Price
- WSC $22.69
- NUVL $80.96
- Analyst Decision
- WSC Buy
- NUVL Strong Buy
- Analyst Count
- WSC 7
- NUVL 11
- Target Price
- WSC $36.00
- NUVL $120.91
- AVG Volume (30 Days)
- WSC 2.0M
- NUVL 389.1K
- Earning Date
- WSC 10-29-2025
- NUVL 11-11-2025
- Dividend Yield
- WSC 1.23%
- NUVL N/A
- EPS Growth
- WSC N/A
- NUVL N/A
- EPS
- WSC 0.59
- NUVL N/A
- Revenue
- WSC $2,352,581,000.00
- NUVL N/A
- Revenue This Year
- WSC N/A
- NUVL N/A
- Revenue Next Year
- WSC $3.15
- NUVL N/A
- P/E Ratio
- WSC $38.80
- NUVL N/A
- Revenue Growth
- WSC N/A
- NUVL N/A
- 52 Week Low
- WSC $21.91
- NUVL $55.54
- 52 Week High
- WSC $42.15
- NUVL $110.00
- Technical
- Relative Strength Index (RSI)
- WSC 36.95
- NUVL 57.46
- Support Level
- WSC $22.52
- NUVL $77.88
- Resistance Level
- WSC $23.66
- NUVL $83.09
- Average True Range (ATR)
- WSC 0.70
- NUVL 3.23
- MACD
- WSC 0.06
- NUVL 0.21
- Stochastic Oscillator
- WSC 9.17
- NUVL 75.49
About WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.